ZA202200964B - Salts of a compound, crystal forms of the salts and preparation method and use thereof - Google Patents

Salts of a compound, crystal forms of the salts and preparation method and use thereof

Info

Publication number
ZA202200964B
ZA202200964B ZA2022/00964A ZA202200964A ZA202200964B ZA 202200964 B ZA202200964 B ZA 202200964B ZA 2022/00964 A ZA2022/00964 A ZA 2022/00964A ZA 202200964 A ZA202200964 A ZA 202200964A ZA 202200964 B ZA202200964 B ZA 202200964B
Authority
ZA
South Africa
Prior art keywords
salts
compound
preparation
crystal forms
crystal
Prior art date
Application number
ZA2022/00964A
Other languages
English (en)
Inventor
Lei Yin
Zhenglin Yao
Original Assignee
Gan & Lee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74040655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA202200964(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gan & Lee Pharmaceuticals Co Ltd filed Critical Gan & Lee Pharmaceuticals Co Ltd
Publication of ZA202200964B publication Critical patent/ZA202200964B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2022/00964A 2019-06-21 2022-01-20 Salts of a compound, crystal forms of the salts and preparation method and use thereof ZA202200964B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910542355 2019-06-21
PCT/CN2020/097482 WO2020253875A1 (zh) 2019-06-21 2020-06-22 一种化合物的盐、其晶型以及制备方法与应用

Publications (1)

Publication Number Publication Date
ZA202200964B true ZA202200964B (en) 2022-08-31

Family

ID=74040655

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/00964A ZA202200964B (en) 2019-06-21 2022-01-20 Salts of a compound, crystal forms of the salts and preparation method and use thereof

Country Status (16)

Country Link
US (1) US20220168302A1 (enExample)
EP (1) EP3988546A4 (enExample)
JP (1) JP2022538076A (enExample)
KR (1) KR20220041090A (enExample)
CN (1) CN115708409A (enExample)
AR (1) AR119184A1 (enExample)
AU (1) AU2020296048A1 (enExample)
BR (1) BR112021025944A2 (enExample)
CA (1) CA3144546A1 (enExample)
CL (1) CL2021003438A1 (enExample)
CO (1) CO2022000502A2 (enExample)
IL (1) IL289231A (enExample)
MX (1) MX2022000051A (enExample)
PH (1) PH12021553151A1 (enExample)
WO (1) WO2020253875A1 (enExample)
ZA (1) ZA202200964B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022042738A1 (zh) * 2020-08-31 2022-03-03 甘李药业股份有限公司 一种含cdk4/6抑制剂的药物组合物
US20250332167A1 (en) * 2021-05-17 2025-10-30 Gan & Lee Pharmaceuticals Co., Ltd. Pharmaceutical use of cdk 4/6 inhibitor
EP4696689A1 (en) * 2023-04-04 2026-02-18 Suzhou Kintor Pharmaceuticals, Inc. Salt form and crystal form of chiral heterocyclic compound having hedgehog pathway antagonist activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途

Also Published As

Publication number Publication date
CA3144546A1 (en) 2020-12-24
EP3988546A4 (en) 2023-05-17
EP3988546A1 (en) 2022-04-27
AR119184A1 (es) 2021-12-01
KR20220041090A (ko) 2022-03-31
MX2022000051A (es) 2022-05-24
CO2022000502A2 (es) 2022-01-28
US20220168302A1 (en) 2022-06-02
AU2020296048A1 (en) 2022-02-10
BR112021025944A2 (pt) 2022-02-08
CN115708409A (zh) 2023-02-21
PH12021553151A1 (en) 2022-07-25
WO2020253875A1 (zh) 2020-12-24
CL2021003438A1 (es) 2022-09-30
JP2022538076A (ja) 2022-08-31
IL289231A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
ZA202001447B (en) M-diamide compound and preparation method therefor and use thereof
IL276692B (en) Salts, crystalline forms, and methods of their production
EP3628007A4 (en) NEW SALTS AND CRYSTALS
EP3717484A4 (en) PROCESS FOR THE PRODUCTION OF LUMATEPERON AND ITS SALT
IL289453A (en) Process for the preparation of ridinilazole and crystalline forms thereof
IL285378A (en) Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
GB2603382B (en) A pyridine sulfonamide phosphate compound, preparation method therefor, and use thereof
IL288348A (en) Synthesis method of furoimidazopyridine compound, crystal form of furoimidazopyridine compound, and crystal form of salt thereof
LT3845215T (lt) Geriamieji tirpalai, apimantys lizdeksamfetamino druskas
IL289231A (en) Salts of compounds, their crystalline forms and their uses
PL3712304T3 (pl) Diament polikrystaliczny oraz sposób jego wytwarzania
EP3530650A4 (en) CRYSTALLINE FORM OF (R) -4-HYDROXY-2-OXO-1-PYRROLIDINE ACETAMIDE, PRODUCTION METHOD THEREFOR, AND USE THEREOF
ZA202107810B (en) Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof
ZA202105344B (en) Sulcardine salts
IL282817A (en) New material, production method, and its use
IL272835A (en) Salts of a compound and crystalline forms thereof
ES3065261T3 (en) Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
GB201918401D0 (en) Novel crystalline forms of Flufenacet, methods for their preparation and use of the same
GB201918391D0 (en) Novel crystalline forms of flufenacet, methods for their preparation and use of the same
ZA202007034B (en) The crystalline forms of a compound
IL292206A (en) The salts of a compound and its crystalline forms
PL3750893T3 (pl) Związek dioksazoliny, sposób jego wytwarzania oraz jego zastosowania
ZA201900274B (en) Crystal forms of a 9-aminomethyl substituted tetracycline compound and a preparation method thereof
EP3461823A4 (en) PLX3397 HYDROCHLORIDE CRYSTAL FORM, MANUFACTURING METHOD AND USE THEREOF
EP4039678A4 (en) CONNECTION AND PRODUCTION METHOD AND USE THEREOF